Drugs / Avobenzone
Avobenzone
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SHADE UVAGUARD | — | 1992-12-07 | fda.gov ↗ |
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05736224 | May → Sep 2023 | skin cancer | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03582215 | Jul 2018 → Feb 2019 | skin sensitivity to sun | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01001975 | Jul → Aug 2009 | skin sensitivity to sun | Bayer | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05865431 | Mar 2017 → Feb 2018 | hyperpigmentation of the skin | University of California, Davis | Completed | No outcome recorded |
| — | NCT00530387 | Jul 2008 → Jul 2011 | photoallergic dermatitis | NHS Tayside | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01695356 Comparator | Sep 2012 → Oct 2013 | hyperpigmentation of the skin | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | avobenzone | “The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and...” NCT05736224 ↗3“Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole” NCT01001975 ↗ “Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule” NCT03582215 ↗ |
| Known as | 290-400 nm sunscreen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01695356 ↗ |
| Known as | Avobenzona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Known as | Avobenzone component of anthelios sx | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Known as | Avobenzone component of capital soleil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Known as | Avobenzone component of shade uvaguard | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Known as | Butyl-methoxy-dibenzoylmethane | “Butyl-methoxy-dibenzoylmethane” NCT00530387 ↗ |
| Known as | Escalol 517 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Known as | Eusolex 9020 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Known as | Neoheliopan 357 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Known as | NSC-758680 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Known as | Parsol 1789 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200522 ↗ |
| Modality | Small molecule | — CHEMBL1200522 ↗ |
| Route | Topical | “A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the...” NCT01695356 ↗ |